Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Century Therapeutics Inc (IPSC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IPSC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.25
1 Year Target Price $4.25
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.78% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.39M USD | Price to earnings Ratio - | 1Y Target Price 4.25 |
Price to earnings Ratio - | 1Y Target Price 4.25 | ||
Volume (30-day avg) 6 | Beta 1.79 | 52 Weeks Range 0.34 - 2.05 | Updated Date 08/15/2025 |
52 Weeks Range 0.34 - 2.05 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.38 | Actual -0.38 |
Profitability
Profit Margin -19.1% | Operating Margin (TTM) 67.95% |
Management Effectiveness
Return on Assets (TTM) -5.59% | Return on Equity (TTM) -10.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -65058684 | Price to Sales(TTM) 0.41 |
Enterprise Value -65058684 | Price to Sales(TTM) 0.41 | ||
Enterprise Value to Revenue 1.96 | Enterprise Value to EBITDA 0.08 | Shares Outstanding 86158800 | Shares Floating 45127373 |
Shares Outstanding 86158800 | Shares Floating 45127373 | ||
Percent Insiders 24.92 | Percent Institutions 47.3 |
Upturn AI SWOT
Century Therapeutics Inc
Company Overview
History and Background
Century Therapeutics, Inc. was founded in 2018 and is focused on developing allogeneic cell therapies to create cancer cures. It went public in June 2020. The company aims to overcome limitations of existing cell therapies through genetic engineering and cell manufacturing.
Core Business Areas
- Allogeneic Cell Therapies: Develops off-the-shelf allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for treating hematologic malignancies and solid tumors.
- iPSC Platform: Utilizes a proprietary iPSC platform to generate engineered immune cells with enhanced functionality and persistence.
- Genetic Engineering: Applies genetic engineering techniques to modify iPSCs and enhance the therapeutic potential of derived immune cells.
Leadership and Structure
Century Therapeutics is led by a management team with experience in cell therapy development and commercialization. The company has a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- CNT-4003: An Allo-gamma9delta2 CAR-iT cell product candidate targeting solid tumors. It is in Phase 1 clinical trials. Competitors include companies developing CAR-T therapies for solid tumors, such as Allogene Therapeutics and Adaptimmune.
- CNT-7034: An Allo-iNK cell product candidate targeting hematological malignancies. It is in preclinical development. Competitors include companies developing NK cell therapies, such as Fate Therapeutics and Nkarta.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, with significant advancements in CAR-T cell and NK cell therapies for cancer treatment. There's increasing focus on allogeneic approaches to address limitations of autologous therapies.
Positioning
Century Therapeutics is positioned as an innovator in the allogeneic cell therapy space, leveraging its iPSC platform to create off-the-shelf therapies with improved efficacy and safety profiles. The company focuses on both solid tumors and hematological malignancies.
Total Addressable Market (TAM)
The total addressable market for cell therapies is projected to reach tens of billions of dollars in the coming years. Century Therapeutics aims to capture a significant share of this market by developing innovative allogeneic cell therapies.
Upturn SWOT Analysis
Strengths
- Proprietary iPSC platform
- Expertise in genetic engineering
- Strong preclinical data
- Focus on allogeneic cell therapies
Weaknesses
- Early stage of development
- High research and development costs
- Reliance on partnerships
- Cash burn rate
Opportunities
- Expanding clinical pipeline
- Partnerships with pharmaceutical companies
- Regulatory approvals for cell therapies
- Advancements in cell manufacturing technologies
Threats
- Competition from other cell therapy companies
- Clinical trial failures
- Regulatory hurdles
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- ALLO
- CRIS
- NKarta, Inc (NKTX)
- Fate Therapeutics (FATE)
Competitive Landscape
Century Therapeutics competes with other cell therapy companies, including those developing CAR-T cell and NK cell therapies. The company differentiates itself through its iPSC platform and focus on allogeneic therapies.
Growth Trajectory and Initiatives
Historical Growth: The company is still in its early stages of growth, focusing on preclinical and clinical development of its cell therapy candidates.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary, but generally project significant revenue potential in the long term.
Recent Initiatives: Focus on advancing its pipeline of allogeneic cell therapies, including CNT-4003 and CNT-7034. Continued investment in iPSC platform and cell manufacturing capabilities.
Summary
Century Therapeutics is an early-stage biotechnology company focused on developing allogeneic cell therapies for cancer treatment using their proprietary iPSC platform. Its strengths lie in its innovative technology and experienced team. However, it faces challenges related to clinical trial execution, regulatory approvals, and competition from established players. Its future depends on successful clinical data and the ability to secure partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Century Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-06-18 | President, CEO & Director Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 140 | Website https://www.centurytx.com |
Full time employees 140 | Website https://www.centurytx.com | ||
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.